Cannabis stocks were mixed on Monday, with CannTrust falling another 5% on news a customer is returning almost three million Canadian dollars worth of its weed and MedMen rallying as it launches delivery service across California.
Aurora announced in April that it would acquire the remaining interest in the provider of hemp-based foods, hemp fiber and hemp nutraceuticals. The acquired business will become a fully owned subsidiary of Aurora and its stock will be delisted from the TSX Venture Exchange. Aurora first invested in Hempco in 2017 to gain early exposure to the hemp-derived CBD market.
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) are significantly positive, and, as a result, the Company will not enroll the high dose cohort in its ongoing Phase 2 study, but will instead proceed directly to initiate a Phase 3 clinical registration study. The Company’s Phase 2 clinical study was designed in accordance with input received from the U.S. FDA.